Literature DB >> 6406606

A simple alternative pathway for hemolytic assay of human complement component C3 using methylamine-treated plasma.

T E Jessen, V Barkholt, K G Welinder.   

Abstract

A quantitative, alternative pathway (AP) hemolytic assay for human complement component C3 has been developed. This AP-C3 assay is inexpensive, rapid, simple, reproducible and insensitive to C3 degradation products. The AP-C3 assay uses rabbit erythrocytes as complement activator and methylamine-treated plasma, depleted of C3 and C4, as complement source. Rabbit erythrocyte sensitivity varies little from batch to batch, and remains unaltered for at least one month in Alsever's solution. Methylamine plasma may be stored at -20 degrees C for 3 months. AP-C3 lysis of 5-25% of erythrocytes is complete in 20 min and does not change subsequently. The AP-C3 assay is optimally stable at 2 mM Mg2+, 5 mM EGTA and at 5 X 10(7) erythrocytes/ml, yet insensitive to at least 20% deviation in these concentrations. The AP-C3 assay is specific to functional C3 and well suited for determination in plasma samples and during C3 preparation. Adding excessive amounts of C3c or plasma components other than C3 does not change the hemolytic response. The level of native C3 in plasma from 14 donors relative to a reference plasma pool ranged from 0.78 to 1.23. The standard deviation of relative C3 determinations did not exceed 2%.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6406606     DOI: 10.1016/0022-1759(83)90338-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Slp is an essential component of an EDTA-resistant activation pathway of mouse complement.

Authors:  C W van den Berg; P Démant; P C Aerts; H Van Dijk
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

2.  Difference in the biological properties of the two forms of the fourth component of human complement (C4).

Authors:  J A Schifferli; G Steiger; J P Paccaud; A G Sjöholm; G Hauptmann
Journal:  Clin Exp Immunol       Date:  1986-02       Impact factor: 4.330

3.  Co-operation between human CR1 (CD35) and CR2 (CD21) in internalization of their C3b and iC3b ligands by murine-transfected fibroblasts.

Authors:  M L Grattone; C L Villiers; M B Villiers; C Drouet; P N Marche
Journal:  Immunology       Date:  1999-09       Impact factor: 7.397

4.  The role of C1, C1-inactivator and C4 in modulating immune precipitation.

Authors:  J A Schifferli; G Steiger; M Schapira
Journal:  Clin Exp Immunol       Date:  1985-06       Impact factor: 4.330

5.  Activation of the human complement alternative pathway by Listeria monocytogenes: evidence for direct binding and proteolysis of the C3 component on bacteria.

Authors:  J Croize; J Arvieux; P Berche; M G Colomb
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

6.  The expression of Fc and complement receptors in young, adult and aged mice.

Authors:  V Vĕtvicka; L Fornůsek; J Zídková
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

7.  Serum-induced potentiation of tumor necrosis factor alpha production by human monocytes in response to staphylococcal peptidoglycan: involvement of different serum factors.

Authors:  E Mattsson; J Rollof; J Verhoef; H Van Dijk; A Fleer
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

8.  Inhibition of immune complex solubilization by sera of patients with membranoproliferative glomerulonephritis.

Authors:  T R Welch; A Kleesattel; L Beischel
Journal:  Clin Exp Immunol       Date:  1988-04       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.